This program is nonpromotional and is sponsored by Sanofi and Regeneron Pharmaceuticals. The speaker is being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this presentation. The content contained in this program was jointly developed by the speaker, Sanofi, and Regeneron and is not eligible for continuing medical education (CME) credits.
Distilled into 4 minutes, this session from the Relevant Advanced Practice Immuno-Dermatology Symposium (RAPIDS) 2026 Conference covers the central role of Type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, and dismantles prevalent scientific misconceptions about these inflammatory skin conditions. Jason Hawkes examines how IL-4, IL-13, and IL-31 work together to drive Type 2 inflammation, and why the differences between them matter clinically.
Speaker
Jason Hawkes1
- Oregon Medical Research Center, Portland; Councilor, International Psoriasis Council, Belleair Bluffs, Florida; National Psoriasis Foundation Medical Board and Scientific Advisory Committee, Alexandria, Virginia, USA
MAT-US-2609200 v1.0 – P 09/2026
